Howells Cliff, Allen Steve, Gupta John, Stillwell Garry, Marsden John, Farrell Michael
Prison Health Task Force, Wellington House, 133-155 Waterloo Road, SE1 8UG, London, UK.
Drug Alcohol Depend. 2002 Jul 1;67(2):169-76. doi: 10.1016/s0376-8716(02)00024-8.
This paper reports results from the first controlled trial of opioid withdrawal treatment in the UK using lofexidine in a prison setting. Seventy-four opioid dependent male inmates at a Southern England prison were randomised to receive either methadone (the standard prison treatment) or lofexidine using a randomised double-blind design. No significant statistical difference between the treatment groups was found in relation to the primary variable of severity of withdrawal symptoms (effect size=0.12). No discernible difference was found in the sitting blood pressure or heart rate of the two groups during the trial. These results provide support for the use of lofexidine for the management of opioid detoxification in the prison setting.
本文报告了英国首次在监狱环境中使用洛非西定进行阿片类药物戒断治疗的对照试验结果。英格兰南部一所监狱的74名阿片类药物依赖男性囚犯采用随机双盲设计，被随机分配接受美沙酮（标准监狱治疗方法）或洛非西定治疗。在戒断症状严重程度这一主要变量方面，治疗组之间未发现显著统计学差异（效应大小=0.12）。试验期间，两组的坐位血压或心率未发现明显差异。这些结果为在监狱环境中使用洛非西定管理阿片类药物脱毒提供了支持。
